发明名称 Benzimidazole analogues for the treatment or prevention of flavivirus infections
摘要 Compounds represented by formula I:; or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B′, X, Y, R1, R1′, R2, R2′, R3, R3′, R5, R5′, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
申请公布号 US8765731(B2) 申请公布日期 2014.07.01
申请号 US201213678854 申请日期 2012.11.16
申请人 Vertex Pharmaceuticals Incorporated 发明人 Henderson James A.;Maxwell John;Vaillancourt Louis;Morris Mark;Grey, Jr. Ronald;Giroux Simon;Chan Chun Kong Laval;Das Sanjoy Kumar;Liu Bingan;Poisson Carl;Cadilhac Caroline;Bubenik Monica;Reddy T. Jagadeeswar;Falardeau Guy;Yannopoulos Constantin;Wang Jian;Pereira Oswy Z.;Bennani Youssef L.;Pierce Albert C.;Bhisetti Govinda Rao;Cottrell Kevin M.;Marone Valerie
分类号 A61K31/4184;A61K31/496;A61K31/4545;A61K31/506;A61K31/4439;C07D495/04;C07D417/14;C07D413/14;C07D409/14;C07D405/14 主分类号 A61K31/4184
代理机构 代理人 Lin Min
主权项 1. A compound of formula (IIB): or pharmaceutically acceptable salts thereof, wherein each A is independently C6-14 aryl, 4-12 membered heterocycle, C3-10 cycloalkyl, or 5-12 membered heteroaryl; B and B′ are each independently absent, C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl; R1 is halogen, —ORa, —NRaRb, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, —P(═O)ORaORb, C1-6 alkyl which is unsubstituted or substituted one or more times by R10, C2-6 alkenyl which is unsubstituted or substituted one or more times by R10, C2-6 alkynyl which is unsubstituted or substituted one or more times by R10, or any two occurrences of R1 can be taken together with the atoms to which they are attached to form a 5-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 5-7 membered heterocycle which is unsubstituted or substituted one or more times by R12; Ra-Rd are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R2′ and R2 are each independently halogen, C1-10 alkyl, C1-6 halogenated alkyl, —(CH2)1-6OH, —ORa, —C(═O)ORa, —NRaRb, —NRbC(═O)Ra, —C(O)NRaRb, —S(O)0-3Ra, C6-12 aryl, or 5-12 membered heteroaryl; R3 and R3′ are each independently H, C1-18 alkyl which is unsubstituted or substituted one or more times by R10, C2-12 alkenyl which is unsubstituted or substituted one or more times by R10, C2-12 alkynyl which is unsubstituted or substituted one or more times by R10, C6-14 aryl which is unsubstituted or substituted one or more times by R11, C7-16 aralkyl which is unsubstituted or substituted one or more times by R11, 5-12 membered heteroaryl which is unsubstituted or substituted one or more times by R11, 6-18 membered heteroaralkyl which is unsubstituted or substituted one or more times by R11, 3-12 membered heterocycle which is unsubstituted or substituted one or more times by R12, or 4-18 membered heterocycle-alkyl which is unsubstituted or substituted one or more times by R12; X and Y are each independently  or a bond; wherein the asterisk (*) indicates the point of attachment to the nitrogen of ring C or C′; R4 is H, C1-6alkyl, or halogenated C1-6alky; R5 and R5′ are each independently halogen, —NRaRb, —C(O)NRaRb, —(CH2)1-6OH, C1-6 alkyl, C1-6 halogenated alkyl, hydroxyl, C6-14 aryl, or C1-6 alkoxy; wherein two occurrence of R4 can be taken together with the atoms to which they are attached to form a C1-6alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12; wherein two occurrence of R4′ can be taken together with the atoms to which they are attached to form a C1-6 alkenyl which is unsubstituted or substituted one or more times by R10, a 3-7 cycloalkyl which is unsubstituted or substituted one or more times by R11 or a 4-7 membered heterocycle which is unsubstituted or substituted one or more times by R12; wherein Ra-Rb are each independently H, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; R6 and R6′ are each independently H, C1-6alkyl, —(CH2)1-6OH, C2-6alkenyl, or C2-6alkynyl; m, and n, combined are 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q′ is 0, 1 or 2; q and r are each independently 0, 1, 2, 3 or 4; R10 is halogen, —ORa, oxo, —NRaRb, ═NO—Rc, —C(═O )ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb; R11 is halogen, —ORa, —NRaRb, —C(═O)ORa, C(O)NRaRb, —C(═O)OH, —C(═O)Ra,—C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18 membered heterocycle-alkyl; and R12 is halogen, —ORa, oxo, —NRaRb, ═NO—Rc, —C(═O)ORa, —C(O)NRaRb, —C(═O)OH, —C(═O)Ra, —C(═NORc)Ra, —C(═NRc)NRaRb, —NRdC(═O)NRaRb, —NRbC(═O)Ra, —NRdC(═NRc)NRaRb, —NRbC(═O)ORa, —OC(═O)NRaRb, —OC(═O)Ra, —OC(═O)ORa, hydroxyl, nitro, azido, cyano, —S(O)0-3Ra, —SO2NRaRb, —NRbSO2Ra, —NRbSO2NRaRb, or —P(═O)ORaORb, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C7-16 aralkyl, 5-12 membered heteroaryl, 6-18 membered heteroaralkyl, 3-12 membered heterocycle, or 4-18membered heterocycle-alkyl.
地址 Boston MA US